Navigation Links
MS Drug Helps Reduce Vision Loss

A drug that slows disability and reduces relapse rates in multiple sclerosis (MS) has been found to also reduce vision loss in patients with relapsing MS. //Vision loss is one of the most common and debilitating symptoms of MS. The findings are published in the April 17, 2007, issue of Neurology?, the scientific journal of the American Academy of Neurology.

The analyses were performed on data from the AFFIRM and SENTINEL studies, which involved 2,138 men and women with relapsing multiple sclerosis from clinics in Europe, North American, Australia, and New Zealand. More than half of the people received the drug natalizumab every four weeks for two years. The rest of the group received placebo. Researchers used eye charts of low contrast letters to test the vision of the participants every 12 weeks.

The study found vision loss, defined as a worsening in score by two rows of letters on the eye chart, was reduced by as much as 47 percent among people taking natalizumab compared to those taking placebo.

"Not only does natalizumab prevent the worsening of vision loss in people with relapsing MS, we also found the drug was associated with significant reductions in the likelihood of sustained vision loss," said study author Laura J. Balcer, MD, MSCE, with the University of Pennsylvania School of Medicine in Philadelphia, PA, and member of the American Academy of Neurology. "Specifically, this drug may have implications for preventing further sustained vision loss due to inflammatory demyelination of nerve fibers that connect to the eye, which is common in MS."

However, Balcer said the potential benefits of natalizumab treatment must be weighed with the drug's potential risks or complications, including the rare, often lethal brain disease progressive multifocal leukoencephalopathy (PML), of which three confirmed cases have been reported.

In addition, data from AFFIRM and SENTINEL studies showed that low-contrast le tter acuity eye chart testing is effective for assessing visual outcomes in future MS clinical trials, which have not typically included visual testing components despite vision loss being a main disability of MS.

Source-Eurekalert/L
'"/>




Related medicine news :

1. Antibiotics Helps Autism
2. Serum Progesterone Helps Stratify Ectopic Pregnancy Risk
3. Prescription Drug - Helps People Stop Smoking
4. New Drug PP188 Helps Sickle Cell Disease
5. Red Wine Helps Fight Heart disease
6. Creatine Helps Strengthen Older Men
7. Cholesterol Drug Helps After Angioplasty
8. Virus Helps Remove Brain Cancer
9. Eating Fish Helps the Heart
10. Antidepressant Helps Relieve Hot Flashes
11. Epilepsy Drug Helps Diabetic Nerve Damage
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: